Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Dec 15;204(12):1822-6.
doi: 10.1093/infdis/jir653. Epub 2011 Oct 12.

Time to refocus on HSV interventions for HIV prevention?

Clare Tanton, Laith J Abu-Raddad, Helen A Weiss
Comment

Time to refocus on HSV interventions for HIV prevention?

Clare Tanton et al. J Infect Dis. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Impact of high-dose valacylovir treatment on human immunodeficiency virus (HIV) transmission and the HIV epidemic. A, The reduction in HIV transmission probability per coital act expected with a reduction in HIV plasma viral load. The X marker signifies the reduction in infectiousness expected with a reduction of 1 log10 copies/mL in HIV plasma viral load, similar to the viremia reduction observed by Mugwanya et al. B, Impact of intervention aimed at reducing community-level HIV plasma viral load on HIV prevalence and incidence rate at endemic equilibrium. The X marker signifies the impact on prevalence and incidence if the community-level viral load is reduced at the population level by similar magnitude to that observed in Mugwanya et al.
See this image and copyright information in PMC

Comment on

References

    1. Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared to standard dose acyclovir among HIV-1/HSV-2 co-infected persons: a randomized, cross-over trial. J Infect Dis. 2011 204:1912–7. - PMC - PubMed
    1. World Health Organization. Herpes simplex virus type 2: programmatic and research priorities in developing countries (Report of a WHO/UNAIDS/LSHTM Workshop; London 14–16 February 2001) Geneva: WHO/UNAIDS: 2001. http://www.who.int/hiv/pub/sti/en/hiv_aids_2001.05.pdfAccessed 30 September 2011.
    1. Baeten JM, Strick LB, Lucchetti A, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis. 2008;198:1804–8. - PMC - PubMed
    1. Cowan FM, Pascoe SJ, Barlow KL, et al. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect. 2008;84:548–53. - PubMed
    1. Delany S, Mlaba N, Clayton T, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS. 2009;23:461–9. - PMC - PubMed

Publication types

MeSH terms